Quality Policy

14th February 2022

Life Science Group's Quality Policy is to assist our customers in obtaining products of the highest quality to their individual requirements and to provide a service to our customers which consistently satisfies their needs and expectations.

This level of quality is achieved through constantly maintaining and reviewing our current procedures so that they reflect the competence of the Company to existing customers, potential customers and independent auditing and regulatory authorities. All staff are made aware of the objectives of the Quality Policy and that they are individually responsible for the quality of their work. To achieve and maintain the required level of assurance the Managing Director retains responsibility for the Quality System.

The objectives of the Quality Assurance System:

a) Continue to develop antibody sales in 2022
b) Maintain ISO 13485:2016 certification in 2022
c) Register additional products as IVD medical devices in 2022
d) Transfer all raw stock and consumables into SAGE by end February 2022.
e) Update / review QMS according to new rules during 2022
f) Develop LIMS system in 2022
g) Create GMP manufacturing space and register with MHRA during 2022
h) Create fully integrated systems to handle all stock movements in 2022

Additionally, we intend to further improve our quality and product by ensuring the following:

a) Monitoring and analysing customer feedback.
b) Monitoring and analysing trends in customer complaints and non-conformances.
c) Ongoing staff training through external courses, on-site training and regular staff meetings.
d) Internal audits.
e) Customer audits.

Jennifer Murray
Managing Director
Life Science Group Ltd
14th February 2022